Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 LtdfiledCriticalGlaxosmithkline Ip No 2 Ltd
Priority claimed from PCT/EP2013/058249external-prioritypatent/WO2013160222A1/en
Publication of MA20150066A1publicationCriticalpatent/MA20150066A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La présente invention concerne une méthode de traitement de dermatoses répondant aux stéroïdes chez un mammifère, y compris un être humain, en ayant besoin, qui comprend l'administration d'une quantité thérapeutiquement efficace d'un composé choisi dans le groupe constitué par : le n-{(1s)-2-amino-1-[(3-fluorophényl)méthyl]éthyl}-5-chloro-4-(4-chloro-1-méthyl-1h-pyrazol-5-yl)-2-thiophènecarboxamide ou un sel pharmaceutiquement acceptable de celui-ci, et le composé n-{(1s)-2-amino-1-[(3,4-difluorophényl)méthyl]éthyl}-5-chloro-4-(4-chloro-1-méthyl-1h-pyrazol-5-yl)-2- furancarboxamide ou un sel pharmaceutiquement acceptable de celui-ci, à un tel mammifère.The present invention relates to a method of treating steroid-responsive dermatoses in a mammal, including a human being, in need thereof, which comprises administering a therapeutically effective amount of a compound selected from the group consisting of: n - {(1s) -2-amino-1 - [(3-fluorophenyl) methyl] ethyl} -5-chloro-4- (4-chloro-1-methyl-1h-pyrazol-5-yl) -2- thiophenecarboxamide or a pharmaceutically acceptable salt thereof, and the compound n - {(1s) -2-amino-1 - [(3,4-difluorophenyl) methyl] ethyl} -5-chloro-4- (4-chloro) 1-methyl-1H-pyrazol-5-yl) -2-furancarboxamide or a pharmaceutically acceptable salt thereof, to such a mammal.
MA37430A2012-04-242013-04-22
Process for the treatment of steroid-responsive dermatoses
MA20150066A1
(en)
(s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrroli dine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl )acrylamide for the treatment of cancer.
4-hydroxy-2-methyl-5- (propan-2-ylidene) cyclohex-3-enecarbaldehyde for the prevention and treatment of cognitive, neurodegenerative or neuronal disease